~~<i id='C2A60EDA2E'><strike id='C2A60EDA2E'><tt id='C2A60EDA2E'><pre id='C2A60EDA2E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

comprehensive

author：hotspot 2025-09-02 05:48:15 - browse：29

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Cosmetics set for new safety regulation. Why the industry is on board

knowledge

entertainment

hotspot

explore

Wikipedia

explore

CatrionaJamieson,directoroftheSanfordStemCellInstituteattheUniversityofCalifornia,SanDiego,hassentst

WSS

Health care needs a new profession: neuroimaging counseling

Why hospitals are withdrawing from US News rankings

At Orexo, a ‘turning point’ for everything but digital health

UnitedHealth financials solid despite Change Healthcare cyberattack

More tobacco lobbyists active in statehouses

Orangutan used medicinal plant to treat wound, first time ever seen

explore

comprehensive

knowledge

Sports medicine is finally prioritizing gender equality

Why hospitals are withdrawing from US News rankings

As demand for Covid shots wanes, Moderna seeks its next success

Medical bills so high, Medicare adding extra digits to claim forms

ChatGPT in medicine: STAT answers readers' burning questions

Bird flu outbreak in cows is latest avian flu curveball

In age of alternative facts, a scholarly course on calling out crap

Cell therapy fails to slow type 1 diabetes, but safety is established

United colonoscopy coverage change 'may cost lives,' doctors say

Group opposing PBM reform sets lobbying record

entertainment

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

MultiPlan and major insurers sued for alleged medical price

Medical bills so high, Medicare adding extra digits to claim forms

Q&A: Jennifer Adair on making gene therapy available globally

Startup Neumora takes a novel depression drug to Phase 3

MultiPlan and major insurers sued for alleged medical price

hotspot

explore

Wikipedia

explore